Synthetic lethal approaches being investigated in tumor-agnostic studies include PARP inhibitors for BRCA1/2- or ATM-mutant cancers (Schram et al. 2023a); ATR inhibitors for ATM-mutant cancers (Yap et al. 2021); and PKMYT1 inhibition for solid tumors with CCNE1 amplification, FBXW7 loss, and PPP2R1A mutations (NCT04855656). The gene discussed is PPP2R1A; the disease is neoplasm.